Table 2.
The significant alteration in the concentrations of markers of neuroinflammation and neurodegeneration in the blood plasma of patients in the TLE and control groups.
| Plasma Marker Concentration | TLE Patients (Drug-Resistant) Me [LQ; UQ] |
TLE Patients (HS+) Me [LQ; UQ] |
TLE Patients (Drug Responsible) Me [LQ; UQ] |
TLE Patients, Me [LQ; UQ] |
Control Group, Me [LQ; UQ] |
P* |
|---|---|---|---|---|---|---|
| BDNF (ng/mL) | 25.98 * [22.06; 31.29] | 26.28 * [22.73; 31.27] | 24.44 * [19.56; 32.62] | 25.87 * [20.81; 32.17] | 74.85 [45.11; 128.85] | <0.001 |
| TNFa (pg/mL) | 11.44 * [9.42; 16.45] | 11.27 * [8.41; 18.68] | 10.85 * [10.29; 18.35] | 12.30 * [10.27; 20.95] | 73.40 [56.42; 92.88] | <0.001 |
| HMGB1 (pg/mL) | 119.09 * [113.55; 126.93] | 134.65 * [113.19; 156.11] | 135.765 * [114.17; 159.53] | 135.765 * [114.17; 159.53] | 161.73 [136.34; 179.01] | 0.034 |
| NTRK-2 (pg/mL) | 4.40 * [2.60; 5.50] | 4.15 * [3.05; 4.65] | 3.80 * [3.075; 4.83] | 3.80 * [2.90; 4,70] | 3.00 [2.40; 4.80] | 0.365 |
*—Mann–Whitney criterion; Me—median; LQ—lower quartile; UQ—upper quartile; TLE—temporal lobe epilepsy; HS+—hippocampal sclerosis.